Fulgent Genetics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Temple cityUnited statesUniversity of southern californiaExchange commissionFulgent genetics incMoffitt cancer centerAmerican society for clinical oncologyFulgent pharmaFulgent geneticsAmerican societyClinical oncologyAnnual meetingNeck cancerPoster sessionPoster boardSouthern california

Fulgent Announces Second Drug in Development and New Prenatal Genetic Test

El Monte-based genetic testing and analysis company Fulgent Genetics Inc., which rode the Covid testing wave, is moving ahead with its post-Covid strategy.

United statesSankt peterburgNew yorkRaymond jamesBrandon perthuisMing hsiehAndrew cooperLos angeles county department of health servicesMoffitt cancer centerBristol myers squibb coFulgent announces second drug in developmentDrug administrationMoffitt centerPrenatal genetic test researchFulgent genetics incNational cancer

Global Rare Disease Diagnostics Market Insights 2024-2030:

Global Rare Disease Diagnostics Market Insights 2024-2030:
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesProgenity incAgilent technologies incMarket developmentLaboratory corporation of america holdingsPerkinelmer incEurofins scientific incAzenta life sciencesInvitae corporationQuest diagnostics incorporatedMedgenome labs ltdInformation on rare diseaseArray technologyCaris life sciencesRoche ltdTechnology array

Fulgent Reports First Quarter 2024 Financial Results

Total Revenue of $64.5 million Core Revenue grows 1% year-over-year to $63.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million .

United statesPaul kimMing hsiehExchange commissionFulgent genetics incFulgent geneticsScore revenueChief executive officerPrecision diagnosticsInvestigational new drugChief financial officerInvestor relationsPrivate securities litigation reform actConsolidated statementMonths ended march

Fulgent Genetics, Inc (NASDAQ:FLGT) Shares Purchased by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund increased its stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) by 5.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,534 shares of the company’s stock after acquiring an additional 668 shares […]

United kingdomUnited statesPiper sandlerAsset management one coStratos wealth partnersSecurities exchange commissionSg americas securitiesTrellus management companyFulgent genetics incFulgent genetics company profileIllinois municipal retirement fundCambridge investment research advisors incFulgent geneticsFree reportMunicipal retirement fundManagement one